guardant health stock — Guardant Health, Inc. (NASDAQ: GH)

Company background

Guardant Health is a precision oncology company focused on non-invasive cancer testing using blood-based “liquid biopsy” assays, genomic profiling platforms, and data-driven decision support tools. Founded to improve oncology diagnostics and therapeutic selection, Guardant Health’s core commercial products include Guardant360, a comprehensive tumor genomic profiling test for advanced cancers; Guardant360 CDx, its FDA-cleared companion diagnostic; Guardant Shield, an early-cancer screening offering; and GuardantINFINITY, a high-sensitivity minimal residual disease (MRD) and monitoring platform. The company also develops the LUNAR program aimed at early-detection screening across multiple tumor types.

Commercial revenues come primarily from clinical oncology testing (therapeutic selection and monitoring) and evolving screening programs. Clinical and early-detection pipelines, regulatory approvals, and payer coverage decisions directly influence revenue growth expectations and therefore investor interest in guardant health stock. As the business bridges laboratory testing, diagnostics software, and real-world data, investors monitor clinical adoption, reimbursement trends, and the company’s progress in scaling testing volumes.

Listing and basic stock information

Guardant Health’s common stock trades under the ticker GH on the Nasdaq exchange. Key listing and disclosure facts investors frequently consult include:

• Ticker symbol: GH
• Exchange: Nasdaq (U.S.)
• Share class: publicly traded common shares (check company filings for any additional classes or ADR structures)
• ISIN and exact listing identifiers: available in company SEC filings and investor relations materials
• IPO date and offer price: available in the firm’s S-1/registration materials and historical filings
• Official investor disclosures: company Investor Relations site and SEC filings (10-K, 10-Q, 8-K) contain authoritative information on the listing, share counts, and corporate actions

For trading and account access, many retail and institutional brokerages provide quotes and execution. Bitget is available as a trading platform for crypto and traditional asset services where supported; for equities exposure, check Bitget’s product availability and trading features in your jurisdiction.

Identifiers and trading details

Investors and traders typically look for the following trading details for guardant health stock:

• Trading hours: Nasdaq regular market hours (U.S. Eastern Time). Pre-market and after-hours sessions may show quotes with lower liquidity.
• Trading currency: U.S. dollars (USD)
• Instruments: common shares, and where available, listed options for hedging or leverage; margin and shorting availability varies by broker
• Liquidity measures: average daily trading volume, bid-ask spreads, and market depth are practical liquidity gauges
• Real-time or delayed quotes: major financial portals, brokerage platforms, and market data vendors provide live or delayed pricing

Access up-to-date quotes and execution services via your broker or a market data provider; check Bitget for platform-specific offerings and tools.

Historical price performance

A historical view of guardant health stock helps place current price levels in context. Over multiple years, GH has shown pronounced volatility typical of growth-oriented diagnostics and biotech firms. Key historical themes to note:

• Long-term trajectory: GH’s multi-year moves have reflected the company’s clinical and commercial milestones, funding rounds, and sector-wide biotech sentiment shifts.
• Notable highs/lows: investors compare current prices to 52-week highs and lows and multi-year peaks tied to positive trial results or strategic partnerships.
• Recent performance: as of the date below, GH has experienced sharp gains over the past 12 months amid regulatory approvals, partnerships, and better-than-expected revenue trends.

For a full time-series review, consult historical price charts and databases offered by major financial portals and brokerage platforms; these sources permit exportable historical time series for analysis.

Financials and valuation metrics

Guardant Health’s equity valuation is driven by underlying financial performance and forward expectations. Typical financial metrics and valuation measures include:

• Revenue trends: examine quarterly and annual topline growth, revenue by product line (e.g., Guardant360 clinical testing vs. Shield screening), and commercial test volumes.
• Profitability: Guardant historically reported operating losses as it scaled commercialization and invested in R&D; net income (or loss) and EPS are essential but may be negative for multiple periods.
• Cash position and debt: cash and short-term investments versus long-term liabilities indicate runway and capital flexibility. Convertible instruments or recent capital raises should be examined in filings.
• Valuation ratios: conventional ratios such as P/E may be not meaningful when the company is loss-making. Alternative measures include price-to-sales (P/S), enterprise value to revenue (EV/Revenue), and forward revenue multiples.

Investors should read the latest 10-Q and 10-K for consolidated financial data and management discussion on revenue drivers, margin trends, and cash-flow outlook. When guardant health stock is loss-making, valuation rests more on growth, margins trajectory, and the probability of clinical/commercial success.

Market statistics and trading characteristics

Important market-statistics for guardant health stock include:

• Market capitalization: dynamic and time-sensitive; check live market data for current market cap.
• Shares outstanding and float: reported in filings; data vendors may lag or differ slightly — verify in the most recent 10-Q/10-K.
• Average daily volume (ADV): indicates typical liquidity and execution ease.
• Beta and volatility: GH typically exhibits higher beta and volatility than the broader market, reflecting sector risk and binary event sensitivity.
• Short interest and option activity: high short interest or elevated option implied volatility can amplify intraday moves.

When using third-party data, cross-check discrepancies with the company’s filings. For guardant health stock, trading characteristics often reflect a mix of institutional interest, event-driven retail trading, and sector momentum.

Drivers of stock performance

Several company-specific and external factors materially affect guardant health stock:

• Regulatory approvals and companion-diagnostic clearances: FDA determinations for Guardant360 CDx or new companion diagnostic indications can expand clinical utility and payer adoption.
• Payer coverage and reimbursement: Medicare and commercial payer policies — particularly coverage of screening and advanced testing — directly affect revenue prospects.
• Clinical trial results and scientific publications: positive MRD, early-detection, or tumor-profiling validation studies can drive adoption.
• Commercial adoption and test volumes: scalable lab capacity, provider awareness, and ordering patterns influence top-line growth.
• Partnerships and collaborations: alliances with pharmaceutical companies, health systems, or research consortia can accelerate use of Guardant platforms in trials and clinical practice.
• Quarterly earnings, guidance, and management commentary: earnings surprises and updated guidance often produce meaningful stock reactions.
• Broader biotech and macro market sentiment: GH is sensitive to sector rotations, interest-rate moves, and risk-on/risk-off dynamics.

Collectively, these drivers contribute to the narrative investors use to value guardant health stock and judge the company’s path to sustainable profitability.

Major corporate events and recent developments

As of the date noted below, several recent material developments have influenced guardant health stock:

• FDA approval (companion diagnostic): Guardant360 CDx received FDA approval as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from a specific targeted regimen. This approval expands Guardant360 CDx’s companion diagnostic indications and underscores the platform’s clinical utility.

• Commercial and payer milestones: Guardant360 CDx’s expanding indications build on its status as an FDA-cleared liquid biopsy for comprehensive genomic profiling and increase its footprint across tumor types. The platform has accrued multiple companion-diagnostic indications and broad payer coverage, contributing to clinical adoption.

• Strategic collaboration: Guardant Health entered a multi-year collaboration with Merck to support development and commercialization efforts using the GuardantINFINITY Smart platform. Collaborations with large pharmaceutical partners often validate the platform’s utility and can lead to incremental revenue through companion-diagnostic or trial testing arrangements.

• Financial performance: Guardant reported preliminary fourth quarter 2025 revenue of $280 million, up 39% year over year, and full-year 2025 sales of $981 million, up 33% year over year — driven by oncology testing and Shield screening volumes. These reported figures signal accelerating growth in core testing lines.

• Stock technicals and momentum: Recent technical indicators showed GH trading materially above short- and medium-term moving averages, with bullish momentum indicators highlighted by data vendors.

Note: data and dates are time-sensitive; see the sources section for verification.

Analyst coverage and market sentiment

Sell-side analysts and data providers monitor guardant health stock for both fundamental results and event-driven catalysts. Analysts publish ratings, revenue/earnings estimates, and price targets that can influence short-term sentiment. Key points:

• Consensus views: analyst consensus typically aggregates buy/hold/sell ratings and computes an average price target; this metric helps gauge market expectations.
• Recent analyst expectations: as companies deliver quarterly results and guidance, analysts update estimates and revise price targets. These revisions can trigger intraday volatility.
• Sentiment amplification: headlines from regulatory approvals, partnerships, or earnings beats can magnify intraday moves, especially when combined with technical momentum.

Analysts’ views are one input among many; investors should interpret ratings cautiously and consult primary disclosures.

Ownership and shareholders

Shareholder composition offers insight into how guardant health stock is held:

• Institutional vs. retail: institutional ownership in large-cap and late-stage biotech companies often forms a substantial share of float, while retail investors can drive short-term volatility.
• Major institutional owners: large mutual funds, ETFs, and healthcare-dedicated investment firms often appear among top holders; verify current holders in the latest 13F and company proxy statements.
• Insider ownership and transactions: executive and board holdings — and any insider buying or selling — are reported in SEC Form 4 filings and can be informative about management conviction.
• Governance implications: ownership concentration and board composition inform corporate governance and strategic decision-making.

For guardant health stock, check the most recent proxy and 13F data to identify major institutional owners and insider transaction patterns.

Risks and considerations for investors

Investing in guardant health stock entails risks typical of diagnostics and precision-oncology companies. Key considerations include:

• Clinical and regulatory risk: test validation, FDA reviews, and future companion-diagnostic clearances are uncertain and may affect adoption.
• Reimbursement and payer risk: Medicare and private-payer coverage decisions are critical for test utilization and revenue sustainability.
• Competition: other companies in liquid biopsy, genomic profiling, and diagnostics may introduce competing products or alternative clinical workflows.
• Commercial execution risk: scaling laboratory operations, managing unit economics, and expanding provider adoption are execution challenges.
• Financial risk and dilution: continued investment in R&D and commercialization may require capital raises or convertible securities that dilute existing shareholders.
• Volatility: biotech and diagnostics stocks often show elevated volatility, and binary event risk (trial outcomes, FDA decisions) can lead to rapid price swings.

This guide does not provide investment advice. Always consult current SEC filings and company guidance before making investment decisions.

Trading and investment instruments

Ways to gain exposure to guardant health stock include:

• Buying common shares: purchase GH shares via brokerage accounts supporting Nasdaq-listed equities.
• Fractional shares and DRIPs: some brokerages enable fractional-share purchases and dividend reinvestment plans where applicable.
• Listed options: if available for GH, options offer hedging or leveraged strategies; note option implied volatility and liquidity.
• Short selling and margin: permitted via brokers subject to eligibility and margin requirements; risk management is essential.

When trading guardant health stock, consider liquidity (average daily volume and bid-ask spreads), option implied volatility for derivatives strategies, and the time horizon (long-term investors should focus on fundamentals; short-term traders emphasize technicals and news flow). Check Bitget for platform-specific trading functionalities and educational tools.

Peers and sector comparison

For context, investors compare guardant health stock to other companies in diagnostics, genomic testing, and precision oncology. Representative peers include companies focused on molecular diagnostics, genomic profiling, and early-cancer detection. Common comparative metrics include:

• Revenue growth and revenue per test
• Gross margin and operating margin trajectories
• R&D and sales & marketing efficiency
• EV/Revenue and P/S ratios for growth comparison
• Clinical pipeline depth and regulatory milestones

Peer benchmarking helps investors understand GH’s market positioning, valuation dispersion, and commercial run rate relative to similar companies.

Investor resources and primary sources

Authoritative and up-to-date sources for guardant health stock information include:

• Company investor relations materials: earnings releases, investor presentations, and SEC filings (10-K, 10-Q, 8-K) provide primary disclosures.
• SEC EDGAR: search for Guardant Health’s filings to verify share counts, financials, and material events.
• Earnings transcripts and investor presentations: management commentary clarifies drivers and near-term priorities.
• Market data providers and brokers: provide real-time quotes, historical charts, and fundamental metrics.

Always verify time-sensitive numeric data at the original source before making decisions.

See also

• Liquid biopsy
• Precision oncology
• Diagnostics industry overview
• Stock market listing terms and definitions
• Basics of biotech investing

References and external links

• Company investor relations and SEC filings (10-K, 10-Q, 8-K) — primary sources for financials and disclosures
• Major financial data providers and brokerage research for quotes, charts, and analyst reports
• News coverage and industry publications reporting regulatory approvals, partnerships, and earnings

Note: the following facts are time-stamped to clarify their reporting context.

Recent news snapshot (time-stamped)

截至 2026-01-27，据 Benzinga 报道：

• The U.S. Food and Drug Administration approved Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from the encorafenib plus cetuximab regimen. This approval is an addition to earlier companion-diagnostic indications and marks the 25th companion diagnostic indication across multiple tumor types for the Guardant360 CDx platform.

• Guardant Health announced a multi-year collaboration with Merck to support development and commercialization of oncology programs using GuardantINFINITY Smart.

• Guardant released preliminary Q4 2025 revenues of $280 million (up 39% year over year) and reported full-year 2025 sales of $981 million (up 33% year over year), with growth driven by oncology testing and Shield screening volumes.

• Market data reported GH trading above short- and medium-term moving averages, with momentum metrics showing a bullish MACD and a neutral-to-warm RSI. Over the prior 12 months, shares had increased by approximately 145% and were trading nearer to 52-week highs.

• Analysts expected the company to report on February 19, 2026, with consensus estimates (as compiled by data providers) suggesting a loss per share around $(0.61) and revenue near $273.83 million for the quarter.

• Analyst consensus price-target averages and Benzinga Edge momentum scores reflected positive sentiment toward the equity at the time of reporting.

Sources: Benzinga market coverage and company press releases as of the date above. Verify current figures and metrics with original filings and live market data.

How to monitor guardant health stock going forward

Practical steps to follow guardant health stock:

1. Track company filings: subscribe to Guardant Health’s investor relations announcements and monitor SEC filings for definitive data on shares, revenue, and material events.
2. Watch regulatory calendars: FDA advisory meetings, PMAs, or companion-diagnostic approvals are high-impact events.
3. Follow payer and coverage updates: Medicare national and local coverage determinations materially affect test utilization.
4. Read earnings materials: earnings releases, management slides, and Q&A sections provide guidance on volumes, ASPs (average selling prices), and revenue mix.
5. Use market data tools: set alerts for price thresholds, option implied volatility spikes, and unusual volume that may signal news flow.
6. Consider technical context: moving-average crossovers, RSI, MACD, and volume-based indicators can help short-term traders interpret momentum — but technicals are supplements, not substitutes, for fundamentals.

For execution and trading features, review Bitget’s platform offerings and educational resources to determine available tools for equities and derivatives exposure.

Final notes and next steps

This guide summarizes the primary considerations for understanding guardant health stock and how company developments feed into valuation and market reactions. For readers seeking to act on GH-related information:

• Verify time-sensitive numeric data at primary sources (company IR and SEC filings).
• Monitor upcoming earnings and regulatory events that commonly move the stock.
• Use Bitget and your brokerage’s research and execution tools to stay informed and manage orders.

Explore Bitget’s platform to learn about market data tools, execution options, and educational resources for following Nasdaq-listed equities and related instruments.

Explore more: For live quotes, charts, and execution tools related to Guardant Health (GH), check your brokerage or Bitget for availability and platform features.